Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hytrebopag plus rhTPO for severe chemotherapy-related thrombocytopenia in solid tumors
ChiCTR2400090506Phase 2Not yet recruiting
- Sponsor
- Zhengzhou Third People's Hospital
- Start
- Oct 2024
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hetrombopag and recombinant human thrombopoietin in Thrombocytopenia, sponsored by Zhengzhou Third People's Hospital. Primary endpoints: Duration of platelet count < 50×10^9/L and Time to platelet recovery to >100×10^9/L. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
hetrombopagrecombinant human thrombopoietin
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on ChiCTR2400090506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090506.